A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).

Authors :: Lee, Elizabeth Katherine
Xiong, Niya
Cheng, SuChun
Polak, Madeline
Krasner, Carolyn N.
Campos, Susana M.
Wright, Alexi A.
Liu, Joyce F.
Shea, Meghan
Yeku, Oladapo O.
Castro, Cesar Martin
Porter, Rebecca L
Stover, Elizabeth
Bouberhan, Sara
Moroney, John William
Penson, Richard T.
Fleming, Gini F.
Matulonis, Ursula A.
Konstantinopoulos, Panagiotis A.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS5628-TPS5628, 1p
Publication Year :: 2023

Full Text Access

Tools